OBJECTIVE: To determine whether the ankle-brachial index (ABI) predicts survival rates among patients with peripheral vascular disease. DESIGN: A retrospective survival analysis of patients with abnormal ABIs who visited the authors' blood-flow laboratory during 1987. The National Death Index was used to ascertain survival status for all patients up to January 1, 1992. Kaplan-Meier and Cox proportional hazards analyses were used to determine the relationship between increasing lower-extremity ischemia, measured by ABI, and survival time. Clinical characteristics controlled for included age, smoking history, gender, and comorbidities, as well as the presence of lower-extremity rest pain, ulcer, or gangrene. SETTING: A university hospital blood-flow laboratory. PATIENTS/PARTICIPANTS: Four hundred twenty-two patients who had no prior history of lower-extremity vascular procedures and who had ABIs < 0.92 in 1987. RESULTS: Cumulative survival probabilities at 52 months' (4.3 years') follow-up were 69% for patients who had ABIs = 0.5-0.91, 62% for patients who had ABIs = 0.31-0.49, and 47% for patients who had ABIs < or = 0.3. In multivariate Cox proportional hazard analysis, the relative hazard of death was 1.8 (95% confidence interval = 1.2-2.9, p < 0.01) for the patients who had ABIs < or = 0.3 compared with the patients who had ABIs 0.5-0.91. Other independent predictors of poorer survival included age > 65 years (p < 0.001); a diagnosis of cancer, renal failure, or chronic lung disease (p < 0.001); and congestive heart failure (p < 0.04). CONCLUSION: The ABI is a powerful tool for predicting survival in patients with peripheral vascular disease. Patients with ABIs < or = 0.3 have significantly poorer survival than do patients with ABIs 0.31-0.91. Further study is needed to determine whether aggressive coronary risk-factor modification, a work-up for undiagnosed coronary or cerebrovascular atherosclerotic disease, or aggressive therapy for known atherosclerosis can improve survival of patients with ABIs < or = 0.3.
OBJECTIVE: To determine whether the ankle-brachial index (ABI) predicts survival rates among patients with peripheral vascular disease. DESIGN: A retrospective survival analysis of patients with abnormal ABIs who visited the authors' blood-flow laboratory during 1987. The National Death Index was used to ascertain survival status for all patients up to January 1, 1992. Kaplan-Meier and Cox proportional hazards analyses were used to determine the relationship between increasing lower-extremity ischemia, measured by ABI, and survival time. Clinical characteristics controlled for included age, smoking history, gender, and comorbidities, as well as the presence of lower-extremity rest pain, ulcer, or gangrene. SETTING: A university hospital blood-flow laboratory. PATIENTS/PARTICIPANTS: Four hundred twenty-two patients who had no prior history of lower-extremity vascular procedures and who had ABIs < 0.92 in 1987. RESULTS: Cumulative survival probabilities at 52 months' (4.3 years') follow-up were 69% for patients who had ABIs = 0.5-0.91, 62% for patients who had ABIs = 0.31-0.49, and 47% for patients who had ABIs < or = 0.3. In multivariate Cox proportional hazard analysis, the relative hazard of death was 1.8 (95% confidence interval = 1.2-2.9, p < 0.01) for the patients who had ABIs < or = 0.3 compared with the patients who had ABIs 0.5-0.91. Other independent predictors of poorer survival included age > 65 years (p < 0.001); a diagnosis of cancer, renal failure, or chronic lung disease (p < 0.001); and congestive heart failure (p < 0.04). CONCLUSION: The ABI is a powerful tool for predicting survival in patients with peripheral vascular disease. Patients with ABIs < or = 0.3 have significantly poorer survival than do patients with ABIs 0.31-0.91. Further study is needed to determine whether aggressive coronary risk-factor modification, a work-up for undiagnosed coronary or cerebrovascular atherosclerotic disease, or aggressive therapy for known atherosclerosis can improve survival of patients with ABIs < or = 0.3.
Authors: M H Criqui; R D Langer; A Fronek; H S Feigelson; M R Klauber; T J McCann; D Browner Journal: N Engl J Med Date: 1992-02-06 Impact factor: 91.245
Authors: Andrew M Wilson; David S Shin; Carlton Weatherby; Randall K Harada; Martin K Ng; Nandini Nair; Jan Kielstein; John P Cooke Journal: Vasc Med Date: 2010-05-19 Impact factor: 3.239
Authors: M Filippella; E Lillaz; A Ciccarelli; S Giardina; E Massimetti; F Navaretta; A Antico; M Veronesi; G Lombardi; A Colao; E Ghigo; A Benso; G Doveri Journal: J Endocrinol Invest Date: 2007-10 Impact factor: 4.256
Authors: B A Muzembo; Y Nagano; N Dumavibhat; N R Ngatu; T Matsui; S A Bhatti; M Eitoku; R Hirota; K Ishida; N Suganuma Journal: J Nutr Health Aging Date: 2013-04 Impact factor: 4.075
Authors: Maya J Salameh; Tatjana Rundek; Bernadette Boden-Albala; Zhezhen Jin; Elizabeth V Ratchford; Marco R Di Tullio; Shunichi Homma; Ralph L Sacco Journal: J Gen Intern Med Date: 2008-06-25 Impact factor: 5.128
Authors: Joachim H Ix; Ronit Katz; Ian H De Boer; Brian R Kestenbaum; Matthew A Allison; David S Siscovick; Anne B Newman; Mark J Sarnak; Michael G Shlipak; Michael H Criqui Journal: J Am Coll Cardiol Date: 2009-09-22 Impact factor: 24.094